Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.